|
HKUST Institutional Repository >
Chemistry >
CHEM Patents >
Please use this identifier to cite or link to this item:
http://hdl.handle.net/1783.1/3364
|
| Title: | 3-Hydroxy-Propanamine derived neuronal reuptake inhibitors |
| Other Titles: | 3-羟基-丙胺衍生的神经元重吸收抑制剂 |
| Authors: | Carlier, Paul R.
Richelson, Elliott
Lo, Ching Kam (盧程錦)
Lo, Man Chu (盧文珠) |
| Keywords: | Antidepressant drugs
Reuptake inhibition profile |
| Issue Date: | 25-Aug-2004 |
| Citation: | 中國專利 ZL 98 1 02833.0 |
| Abstract: | Antidepressants such as Prozac, Paxil and Zoloft, are characterized by an ability to selectively block reuptake of serotonin (5-HT). Selective NE-reuptake inhibitor antidepressants such as Tomoxetine and Vivalan have also been developed. Effexor and Serzone have been termed SNRI antidepressants because they inhibit 5-HT and NE reuptake with similar potency. However, these present drugs are ineffective to some patients. Only new generation of drugs possess reuptake inhibition profile different from those currently known can solve the problem.
The invention relates to the new class of antidepressant compounds, which exhibit synaptosomal reuptake inhibition of neurotransmitters such as serotonin (5-HT), norephinephrine (NE), and dopamin (DA) simultaneously. These new compounds possess special reuptake inhibition profile. The antidepressant properties of these compounds were assayed. The best of these new compounds bind to the transporter protein 175 times stronger than serotonin itself. These compounds will therefore effectively block synaptosomal reuptake of serotonin. |
| Rights: | This patent is also available at HKUST Technology Transfer Center Patent Search at <http://patentsearch.ttc.ust.hk/ListPatentsDetail.asp?id=17> |
| URI: | http://hdl.handle.net/1783.1/3364 |
| Appears in Collections: | CHEM Patents
|
Files in This Item:
| File |
Description |
Size | Format |
|---|
| [CN]ZL98102833.0(TTC.PA.0052)_20041013.pdf | | 554Kb | Adobe PDF | View/Open |
|
All items in this Repository are protected by copyright, with all rights reserved.
|
